Summary: Alcohol Use Disorder (AUD) is increasingly understood by modern medicine not as an isolated behavioral shortcoming, but as a complex, systemic disease tightly interwoven with neuroinflammation. Chronic alcohol exposure causes significant structural damage to the body’s neuroimmune system, prompting brain cells to produce inflammatory signaling proteins that alter neural circuitry and dismantle native behavioral control systems.
A new study reveals that an FDA-approved anti-inflammatory drug commonly used to treat rheumatoid arthritis can drastically cut down excessive, compulsive drinking. The treatment works by blocking interleukin-6 (IL-6), an inflammatory molecule that spikes during heavy drinking and actively suppresses the brain’s natural “braking system” within the central amygdala, the addiction and emotional core of the mind.
By restoring this inhibitory balance, the antibody treatment successfully reduced alcohol consumption in dependent female subjects. Combined with a comprehensive transcriptomic analysis of postmortem human brain tissue, this study provides a powerful, translational molecular avenue for targeted, sex-specific addiction medicine.
Key Facts
- The Amygdala Brake Failure: Chronic alcohol intake induces high levels of IL-6 signaling within the central amygdala. This inflammatory surge directly suppresses the brain’s GABA system—the chemical braking mechanism meant to keep neurons from becoming over-activated and firing uncontrollably.
- The Excitation Conundrum: When IL-6 weakens this GABA braking system, neural over-excitation occurs. This loss of inhibitory control directly sparks the hallmark traits of addiction: compulsive consumption, intense cravings, and severe withdrawal symptoms.
- Repurposing Autoimmune Defense: By administering an antibody designed to block the IL-6 receptor (the exact therapeutic class used to treat severe rheumatoid arthritis), scientists prevented the inflammatory molecule from acting on brain tissue, causing dependent female mice to drink significantly less.
- The Sex-Specific Divide: The anti-IL-6 receptor antibody successfully reduced drinking behaviors in alcohol-dependent female mice, while having no significant effect on dependent males. This divergence aligns with clinical literature showing that human females are significantly more susceptible to autoimmune and dysregulated inflammatory pathways.
- Human Tissue Validation: To bridge the gap between animal models and clinical reality, the team evaluated postmortem brain tissue from 30 individuals diagnosed with AUD and 30 healthy controls. They identified 377 differentially expressed genes, with IL-6 and related neuroinflammatory markers serving as the strongest elevated signals in the AUD group.
- Destigmatizing Through Pathology: Dr. Marisa Roberto emphasizes that classifying AUD as a whole-body, neuroimmune condition shifts public and clinical perspectives away from social stigma, framing excessive drinking as a treatable, biological medical condition.
Source: Scripps Research Institute
The drugs that keep rheumatoid arthritis in check may one day help people stop drinking. A new Scripps Research study shows that an anti-inflammatory molecule, already approved by the U.S. Food and Drug Administration to treat autoimmune diseases, reduces excessive alcohol consumption in alcohol-dependent female mice.
The new findings, published in the Journal of Neuroinflammation on May 22, 2026, add to a growing body of evidence that brain inflammation is involved in alcohol use disorder.
“This disorder is, in part, driven by damage to our neuroimmune system,” says senior author Marisa Roberto, professor of translational medicine and the Paul and Cleo Schimmel Endowed Chair at Scripps Research. “Targeting this system might be an exciting clinical avenue to follow up with in the coming years.”
The new research revolves around a molecule called interleukin-6, or IL-6, which the body produces in response to stress, infection and injury. Best known for its role in driving inflammation in diseases like rheumatoid arthritis, IL-6 is produced not just by immune cells throughout the body but also cells in the brain, where it can directly influence brain circuit functions.
Previous research had already suggested that people who drink heavily tend to have elevated levels of IL-6 in their blood, and that a genetic variant in the IL-6 gene is associated with increased risk of alcohol use disorder. Due to these associations, Roberto’s team wondered whether blocking IL-6 could reduce drinking behavior.
To test that idea, the researchers turned to a mouse model of alcohol use disorder in which animals have escalating and compulsive drinking behavior. They confirmed that chronic alcohol exposure increased levels of IL-6 signaling in the brain’s central amygdala, a region tied to addiction behaviors. They then showed that in alcohol-dependent mice, IL-6 suppresses the central amygdala’s GABA system, which usually prevents neurons from becoming over-activated.
“GABA is an important brake signal that the brain uses to dampen the activity of neurons,” explains co-first author Chloe Erikson, a postdoctoral fellow in the Roberto lab. “When this braking system gets weakened, over-excitation can result. That loss of inhibitory control plays a large role in alcohol use disorder-associated behaviors like alcohol consumption, craving and withdrawal.”
Next, the group gave alcohol-dependent mice an antibody targeting the IL-6 receptor—the same class of drug used for rheumatoid arthritis. The antibody works by binding to the IL-6 receptor, preventing IL-6 from acting on cells throughout the body, including the brain. After receiving the treatment, alcohol-dependent female mice drank significantly less alcohol.
Dependent males (in addition to non-dependent animals of either sex) showed no significant change, suggesting the drug wasn’t broadly suppressing drinking but acting on a specific, dysregulated molecular pathway that drove drinking behavior in the females.
“In the human literature, we know that women are more prone to autoimmune diseases, so while the positive results in our female mice were surprising, they aligned with the clinical data,” says co-first author Celsey St. Onge, also a Scripps Research postdoctoral fellow.
The results point to meaningful biological differences in how male and female brains respond to alcohol use disorder. However, the researchers note that more work is needed to untangle the sex difference; female mice in the study also drank more alcohol than males, which could explain some of the difference in treatment response.
In addition to the mouse studies, the team analyzed postmortem brain tissue from 30 humans diagnosed with alcohol use disorder and 30 people without it. They identified 377 differentially expressed genes between the two groups. Among the strongest signals was IL-6, which was significantly elevated in those with alcohol use disorder, along with several other inflammation-related genes.
Beyond their specific finding, the researchers say the work speaks broadly to how scientists view alcohol use disorder. Roberto’s lab has previously linked another immune protein in the brain to alcohol withdrawal symptoms and has tested a different anti-inflammatory drug for its potential to treat alcohol use disorder.
“There has been a substantial shift in the field in the past few years to classify alcohol use disorder as a whole-body disease,” says Roberto. “With this neuroimmune angle, we add to a growing literature that drinking too much can take a serious toll on your health. It’s our hope that classifying it as such can continue to destigmatize this complex disorder.”
Funding:
This work was supported by funding from the National Institute on Alcohol Abuse and Alcoholism (AA013498, AA017447, AA027700, P60 AA006420, AA029841, AA012404, U01AA020926, R01AA025996, K99AA031718, T32AA007456, U01AA029965, P60AA010760 and R01AA029486), the National Institute on Drug Abuse (R21DA060442), the Schimmel Family Chair, a VA Merit Review Award (I01BX001819), and by facilities and resources at the Portland VA Health Care System.
Key Questions Answered:
A: Rheumatoid arthritis is an autoimmune condition driven by an over-activated immune protein called interleukin-6 (IL-6), which causes severe inflammation in the joints. However, immune cells aren’t the only things that make IL-6, cells in your brain produce it too. The Scripps Research team discovered that chronic alcohol exposure inflicts severe damage on the brain’s neuroimmune landscape, causing a massive surge of IL-6 directly inside the central amygdala. Because an arthritis drug’s sole purpose is to act as a molecular shield that blocks IL-6 receptors, injecting it prevents this inflammatory molecule from warping brain networks, effectively treating the root neuroimmune damage driving the addiction.
A: Your brain relies on a crucial neurotransmitter called GABA to act as a physical brake pedal, dampening down neural activity so your nervous system doesn’t become over-stimulated. When heavy drinking causes IL-6 to flood the central amygdala, this inflammatory protein steps on the brake line, weakening the GABA system. Without its native chemical brakes, the amygdala enters a state of chaotic, unmitigated over-excitation. This loss of inhibitory control is the precise biological engine that creates the maddening loop of alcohol use disorder: constant mental static, intense cravings, physical anxiety, and severe withdrawal symptoms that drive a person to take another drink just to quiet the noise.
A: This sex-based divide is one of the most fascinating clinical findings of the study. In human medicine, it is a well-established fact that females are significantly more prone to autoimmune disorders and hyper-inflammatory conditions than males. The positive response in female mice directly mirrors this human clinical data, suggesting that alcohol use disorder may follow distinct, highly dysregulated inflammatory pathways in female brains compared to male brains. While more work is needed to completely unpack these differences, it highlights a crucial shift toward personalized medicine, proving that future addiction therapies may need to be custom-tailored based on biological sex.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuropharmacology and AUD research news
Author: Press Office
Source: Scripps Research
Contact: Press Office – Scripps Research
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Translational evidence for increased central amygdala IL-6 activity in alcohol dependence” by Celsey M. St. Onge, Chloe Erikson, Bryan Cruz, Vittoria Borgonetti, Joel G. Hashimoto, Jessica A. Cucinello-Ragland, Taylor Fitzpatrick-Schmidt, Larry Rodriguez, Sophia Khom, Michela Palmisano, Roman Vlkolinsky, Christopher S. Oleata, Tali Nadav, Nihal A. Salem, Scott Edwards, R. Dayne Mayfield, Marina Guizzetti, Amanda J. Roberts, Michal Bajo & Marisa Roberto. Journal of Neuroinflammation
DOI:10.1186/s12974-026-03868-2
Abstract
Translational evidence for increased central amygdala IL-6 activity in alcohol dependence
Alcohol use disorder (AUD) is one of the most prevalent mental health disorders worldwide yet effective therapeutics remain limited. Mounting evidence indicates that dysregulated immune signaling in the brain plays a role in AUD pathophysiology.
Activation of pro-inflammatory pathways like the interleukin-6 (IL-6) pathway represents a potential point of convergence between synaptic dysfunction and motivational changes in AUD that remain undiscovered. Thus, using a translational neuroscience approach and well-established model of chronic alcohol intake, we investigated the cell-type specific role of IL-6 signaling in the central amygdala, a critical region in the development and maintenance of alcohol dependence.
We demonstrate that chronic alcohol exposure recruits IL-6-related pathways in humans and rodents via astrocytic, neuronal, and microglial mechanisms, and that IL-6 inhibits central amygdala GABAergic transmission. Notably, systemic administration of an IL-6 receptor antibody decreased alcohol drinking in alcohol-dependent female mice.
Collectively, our findings support IL-6 inhibition as a novel-neuroimmune-targeted therapeutic strategy to reduce excessive drinking in the context of AUD.
